Doody RS. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S21-5. Epub 2007 Dec 21 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate
  2. Rusty Unleashed: Forget Disease Modification, Go for Big Effect
AlzAntibodiesAlzBiomarkerAlzRiskBrain BanksGeneticsAlzGeneHEXMutationsProtocolsResearch ModelsTherapeutics